Day 3 Recap: AAD 2025

Author(s):

Kaitlyn Bader, Assistant Managing Editor

Key Takeaways

Upadacitinib reduces type 1 inflammation and enhances melanocyte biomarkers, showing efficacy in nonsegmental vitiligo.
Risankizumab maintains high skin clearance over 36 months, aligning with psoriasis treatment goals.
Emerging therapies and early intervention strategies for port-wine birthmarks were highlighted at the AAD Annual Meeting.
Key dermatology controversies include AI, molecular testing, and melanoma overdiagnosis, with a focus on addressing disparities in darker skin tones.
Baricitinib demonstrates rapid hair regrowth in adolescents with severe alopecia areata, according to phase 3 BRAVE-AA-PEDS trial data.

Catch up on coverage from the third day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Upadacitinib Shows Biomarker-Driven Efficacy in Nonsegmental Vitiligo

AbbVie’s phase 2 study demonstrates how upadacitinib reduces type 1 inflammation and boosts melanocyte biomarkers to drive vitiligo response.

Risankizumab Maintains High Skin Clearance Over 36 Months

Findings suggest that most patients on risankizumab met or exceeded the National Psoriasis Foundation’s treatment goals.

Advances in Treatment Resistant Port-Wine Birthmarks: Emerging Therapies and Future Directions

Expect exciting news in the treatment of port-wine birthmarks, Kristen Marie Kelly, MD, told AAD Annual Meeting attendees.

Advancing Recognition and Treatment of Allergic Contact Dermatitis

JiaDe Yu, MD, discussed important clinical issues in allergic contact dermatitis at the AAD Annual Meeting.

Early Intervention for Port-Wine Stains

At the AAD Annual Meeting, Roy G. Geronemus, MD, emphasized the importance of early interventions for port wine stains.

Adewole Adamson, MD, MPP: Exploring Key Controversies in Dermatology at the 2025 AAD Annual Meeting

Adamson dives deep into artificial intelligence, molecular testing, and melanoma overdiagnosis.

Addressing Disparities in Inflammatory Skin Diseases in Darker Skin Tones

At AAD 2025, Raj Chovatiya, MD, PhD, MSCI, explored the role of social determinants in AD, HS, and PsO, emphasizing the need for improved clinical recognition and inclusive research.

Late-Breaking Data: Baricitinib Shows Rapid Hair Regrowth in Adolescents With Severe Alopecia Areata

Anabela Cardoso, MD, provides data on the phase 3 BRAVE-AA-PEDS trial, the largest JAK inhibitor study dedicated to adolescents with severe alopecia areata, at AAD.

Michael Gold, MD: Mastering Device Complications and the Importance of Preparedness in Dermatology

Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.

Understanding the Controversies in Lasers and Infantile Hemangiomas

Denise W. Metry, MD, FAAD, explored the controversies in using lasers in infantile hemangiomas at the AAD Annual Meeting.

Stay tuned for more expert insights, clinical research, and late-breaking data from AAD 2025.